SkinnyRx Review: Under an Open FDA Letter, Still Advertising "FDA-Compliant Facilities"

And the sentence still on the page

Here is what SkinnyRx's compounded semaglutide page says today:

"Compounded semaglutide is Prepared in FDA-compliant facilities and undergoes rigorous quality testing before reaching you."

And, among its reasons to choose it:

"Rigorous quality testing at FDA-compliant facilities"

There is no such designation.

A 503A compounding pharmacy — which is what makes patient-specific compounded semaglutide — is licensed and inspected by its state board of pharmacy. FDA does not certify it, does not approve what it makes, and awards no "compliant" status. A 503B outsourcing facility does register with FDA and is subject to FDA inspection, but registration is not a compliance certification either, and SkinnyRx claims neither category by name. The site states no compounding category at all.

So the phrase asserts a regulatory standing that does not exist, on the product line named in an open FDA misbranding letter, at a company that describes the pathway correctly elsewhere on the same page — "may be prescribed by a licensed provider and dispensed by U.S. state-licensed pharmacies". It knows the accurate wording. It uses the other one in the quality claim.

Everything else shaped like evidence

Read SkinnyRx's reasons to buy in order:

"Free shipping directly to your door · Licensed US medical providers review every application · Rigorous quality testing at FDA-compliant facilities · No contracts or commitments – cancel anytime · 4.8-out-of-5 star rating on Trustpilot (highest among GLP-1 providers) · Real, personalized support throughout your journey · Money-back guarantee if you're not approved"

Two of those are checkable and true — free shipping, and a refund if you are declined. The rest are the pattern.

"Rigorous quality testing" is asserted twice across the site. No certificate of analysis, lot number, potency figure, sterility result or named laboratory is published anywhere. No pharmacy is named to ask.

"Clinically supported ingredients", on the semaglutide page, gestures at a literature without naming one item of it. SkinnyRx cites no study, no trial, no publication and no PubMed ID anywhere on its site — for either molecule, both of which have large, genuine phase 3 programmes it could have pointed to. ^{1 2}

"4.8-out-of-5 star rating on Trustpilot (highest among GLP-1 providers)" is a superiority claim about an entire market. No comparison set is given, no method, no date — and star ratings move.

And one line simply misdescribes the drug. The page says compounded semaglutide "helps control hunger, making you feel full longer and boosting your metabolism". The first two are right; a GLP-1 receptor agonist works on appetite signalling and gastric emptying. Boosting metabolic rate is not the mechanism.

The microdose promise

SkinnyRx offers a microdosing programme, described like this:

"By stabilizing your hunger spikes and curbing emotional eating, microdosing makes the process feel like a natural lifestyle shift rather than a battle… appetite and manageable hunger without feeling 'wiped out'. The goal is steady, controlled progress."

That is a comparative tolerability claim: a lower dose gives you the appetite control without the side effects of a full one. It is precisely the kind of claim only a trial comparing the two doses could establish, and no completed trial of a sub-therapeutic semaglutide regimen exists against any endpoint.

Separately, SkinnyRx sells compounded semaglutide tablets. No registered trial has tested a compounded oral semaglutide tablet. The approved oral product is a specific formulation built around an absorption enhancer, and its results do not transfer to a compounded one.

What this means if you are buying

The molecules work. Semaglutide and tirzepatide have large phase 3 programmes behind the approved products, and nothing in SkinnyRx's warning letter suggests a quality problem with what it dispenses.

What you cannot verify is anything SkinnyRx says about itself. No pharmacy is named, no compounding category is stated, no test result is published, no study is cited, and the one quality assurance offered — "FDA-compliant facilities" — describes a status that does not exist. Before buying, ask which pharmacy compounds it and under which category, and ask for a certificate of analysis.

Know that the company is under an open FDA misbranding letter naming these exact products, that it was issued in February 2026, and that no close-out has been recorded. That is a fact worth having, and it is not a reason on its own to walk away.

And treat the microdose page's promise of appetite control "without feeling wiped out" as marketing rather than a finding.